Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.59 |
| ▸ | MMP12 | P39900 | 2/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.58 |
| ▸ | MMP13 | P45452 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6318681 | 0.90 | MMP2 (0.62) | MMP2MMP12MMP3ADAM17MMP13 | |
| SCHEMBL6318457 | 0.88 | MMP2 (0.61) | MMP2MMP12MMP3ADAM17MMP13 | |
| SCHEMBL4199718 | 0.88 | MMP2 (0.67) | MMP2MMP12MMP3ADAM17 | |
| SCHEMBL6321657 | 0.88 | MMP2 (0.54) | MMP2MMP12MMP3ADAM17MMP13 | |
| SCHEMBL6317450 | 0.82 | ADAM17 (0.55) | MMP2MMP12ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL6321656 | 0.79 | MMP2 (0.57) | MMP2MMP12MMP3ADAM17MMP13 | |
| SCHEMBL6321457 | 0.78 | ADAM17 (0.74) | MMP2MMP12MMP3ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL3966506 | 0.77 | MMP2 (0.71) | MMP2MMP12MMP3ADAM17 | |
| SCHEMBL6322313 | 0.77 | ADAM17 (0.69) | MMP2MMP12MMP3ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL3964730 | 0.77 | MMP2 (0.91) | MMP2MMP12MMP3ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936620-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20030166647-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| WO-2003053940-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-$G(A) CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166647-A1 | Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases | TNF, MMP1, ADAMTS1 | MMP2 6/4885MMP12 26/4885MMP3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.